title: Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma.
abstract: Lymphoblastic lymphoma (LBL) is a rare subtype of non-Hodgkin lymphoma. There are limited reports on allogeneic stem cell transplantation (allo-SCT) in patients with LBL. We retrospectively analyzed the clinical outcomes of 15 adult patients with LBL who received allo-SCT at our institution. The median age at allo-SCT was 29 years (range, 18-42). Disease status at the time of transplantation was complete remission (CR), partial remission (PR), and advanced disease in 4, 4, and 7 patients, respectively. The median follow-up duration of survivors was 25 months (range, 6-106). The probabilities of overall survival (OS) and progression-free survival (PFS) at 2 years after allo-SCT were 37% and 24%, respectively. The respective 2-year OS and PFS rates of the 8 patients with CR or PR at the time of transplantation were 57% and 45%, while those with advanced disease were 14% and 0%. In conclusion, the treatment outcomes of allo-SCT in patients with LBL were unsatisfactory. Although outcomes were promising in patients with CR or PR at the time of transplantation, they were dismal in patients with progressive disease. Further advances in chemotherapy, both induction and salvage therapies, are needed to improve the clinical outcomes of patients with LBL.
authors.affiliation: Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Makita
authors.forename: Shigeo
authors.initials: S
authors.lastname: Fuji
authors.forename: Kuniko
authors.initials: K
authors.lastname: Takano
authors.forename: Takashi
authors.initials: T
authors.lastname: Tanaka
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Inoue
authors.forename: Reiko
authors.initials: R
authors.lastname: Ito
authors.forename: Ayumu
authors.initials: A
authors.lastname: Ito
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Kinuko
authors.initials: K
authors.lastname: Tajima
authors.forename: Keiji
authors.initials: K
authors.lastname: Okinaka
authors.forename: Saiko
authors.initials: S
authors.lastname: Kurosawa
authors.forename: Sung-Won
authors.initials: SW
authors.lastname: Kim
authors.forename: Takuya
authors.initials: T
authors.lastname: Yamashita
authors.forename: Ryuji
authors.initials: R
authors.lastname: Tanosaki
authors.forename: Kensei
authors.initials: K
authors.lastname: Tobinai
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fukuda
mesh_terms: D000293:Adolescent; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult